Company ImmunoVaccine Inc. Toronto S.E.
Equities
IMV
CA45254B1031
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- CAD | - |
2023 | Transcript : IMV Inc., Q4 2022 Earnings Call, Mar 16, 2023 | |
2022 | Transcript : IMV Inc., Q3 2022 Earnings Call, Nov 11, 2022 |
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Andrew Hall
CEO | Chief Executive Officer | - | 20-11-09 |
Brittany Davison
DFI | Director of Finance/CFO | - | - |
Chief Operating Officer | - | - | |
Stéphane Fiset
CTO | Chief Tech/Sci/R&D Officer | - | - |
Annie Tanguay
CMP | Compliance Officer | - | - |
Jeremy Graff
CTO | Chief Tech/Sci/R&D Officer | - | 21-06-13 |
Delphine Davan
IRC | Investor Relations Contact | - | 19-07-31 |
Linda Barabe
IRO | Public Communications Contact | - | - |
Ryan Marshall
PRN | Corporate Officer/Principal | - | 15-12-31 |
General Counsel | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 58 | 20-06-30 | |
Kyle Kuvalanka
BRD | Director/Board Member | 56 | 21-03-31 |
Markus Warmuth
BRD | Director/Board Member | 53 | 18-11-05 |
Shabnam Kazmi
BRD | Director/Board Member | - | 23-01-07 |
Andrew Hall
CEO | Chief Executive Officer | - | 20-11-09 |
Brittany Davison
DFI | Director of Finance/CFO | - | - |
Michael Kalos
BRD | Director/Board Member | 62 | 21-05-10 |
Saman Maleki
BRD | Director/Board Member | - | 22-09-14 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 11,711,637 | 11,703,501 ( 99.93 %) | 0 | 99.93 % |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
+18.97% | 45.34B | |
+41.98% | 40.42B | |
-10.06% | 37.92B | |
+31.15% | 31.75B | |
-7.79% | 27.71B | |
+13.32% | 26.52B | |
+43.05% | 13.96B | |
+31.28% | 12.44B | |
-7.41% | 11.26B |
- Stock Market
- Equities
- IMVI.F Stock
- IMV Stock
- Company ImmunoVaccine Inc.